An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
About this trial
This is an interventional treatment trial for Carcinoma, Non-Small-Cell Lung focused on measuring vaccine, lung, cancer, Carcinoma, Large Cell, Non-Small-Cell Lung Carcinoma
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa At least four weeks following prior standard treatment, with no evidence of disease Must use adequate birth control Exclusion Criteria: Prior cancer vaccine therapy or concurrent participation in any other investigational study A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine Women who are pregnant, intend to become pregnant, or who are breast feeding
Sites / Locations
- University of California, Los Angeles
- Cancer Centers of Florida
- New York Oncology Hematology
- Duke University Medical Center
- Mary Crowley Medical Research Center
- Tyler Cancer Center
- University of Washington
- Cancer Care Northwest